Nektar Therapeutics presented preclinical data on its immuno-oncology pipeline candidates, bempegaldesleukin,NKTR-214 or bempeg, a CD122-preferential IL-2 pathway agonist, and NKTR-255, an IL-15 receptor agonist, at the American Association for Cancer Research Annual Meeting 2019. The meeting is being held on March 29 to April 3, 2019 at the Georgia World Congress Center in Atlanta. “We’re excited to showcase our promising immuno-oncology pipeline, which is strategically developed to target multiple points in the cancer immunity cycle to amplify the body’s ability to fight tumor cells,” said Jonathan Zalevsky, Ph.D., Chief Scientific Officer at Nektar. “The preclinical studies presented at AACR 2019, by both Nektar scientists and our collaborators highlight the promise of targeting the IL-2 and IL-15 pathways to activate the immune system to induce durable anti-tumor responses in combination with complementary mechanisms such as personalized T cell vaccines and tumor-directed antibody therapies. We plan to explore these combinations further and look forward to advancing them into the clinic.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.